Kylie O’keefe Sells 15,936 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) insider Kylie O’keefe sold 15,936 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $431,228.16. Following the sale, the insider directly owned 108,864 shares of the company’s stock, valued at $2,945,859.84. This trade represents a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

uniQure Stock Up 2.8%

Shares of QURE stock opened at $27.57 on Friday. The stock’s 50 day simple moving average is $22.52 and its 200 day simple moving average is $21.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. As a group, research analysts predict that uniQure N.V. will post -3.64 EPS for the current year.

Analyst Ratings Changes

QURE has been the topic of a number of recent analyst reports. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Leerink Partners reissued an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a research note on Monday, March 2nd. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $11.00 to $35.00 in a research note on Monday, March 9th. Finally, Barclays cut their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Monday, March 23rd. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.83.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Militia Capital Management LLC acquired a new stake in uniQure in the 1st quarter valued at approximately $1,540,000. Flax Pond Capital LLC grew its holdings in uniQure by 3.8% in the 1st quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock valued at $2,486,000 after buying an additional 5,533 shares during the last quarter. Stempoint Capital LP grew its holdings in uniQure by 79.5% in the 1st quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock valued at $1,276,000 after buying an additional 34,581 shares during the last quarter. Irenic Capital Management LP acquired a new stake in uniQure in the 1st quarter valued at approximately $1,635,000. Finally, Readystate Asset Management LP grew its holdings in uniQure by 39.6% in the 1st quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock valued at $8,252,000 after buying an additional 143,142 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.